2017
Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial
Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial. JAMA Cardiology 2017, 2: 1369-1374. PMID: 29049467, PMCID: PMC5814995, DOI: 10.1001/jamacardio.2017.3655.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticholesteremic AgentsCardiovascular DiseasesCholesterol, LDLCost-Benefit AnalysisDecision Support TechniquesDrug Therapy, CombinationFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaInsuranceInsurance, HealthInsurance, Health, ReimbursementMaleMarkov ChainsMiddle AgedMyocardial InfarctionPCSK9 InhibitorsQuality-Adjusted Life YearsStrokeUnited StatesConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioCost-effectiveness ratioProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsCurrent pricesLife yearsPrivate payersAdditional quality-adjusted life yearPreliminary cost-effectiveness analysisCost-effectiveness standardsProbabilistic sensitivity analysesCost-effectiveness analysisPrivate payer perspectiveCost-effectiveness assessmentNegative returnsHealth system perspectiveSignificant discountUS dollarsDrug pricesPatent protectionPricesStatin treatment strategiesHealth insuranceTime horizonSubtilisin/kexin type 9 inhibitorsReevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach
Chekroud AM, Gueorguieva R, Krumholz HM, Trivedi MH, Krystal JH, McCarthy G. Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach. JAMA Psychiatry 2017, 74: 370-378. PMID: 28241180, PMCID: PMC5863470, DOI: 10.1001/jamapsychiatry.2017.0025.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAffectAgedAntidepressive AgentsBupropionCitalopramCluster AnalysisDepressive Disorder, MajorDose-Response Relationship, DrugDrug Therapy, CombinationDuloxetine HydrochlorideFemaleHumansMaleMianserinMiddle AgedMirtazapineRandomized Controlled Trials as TopicSleepSyndromeTreatment OutcomeVenlafaxine HydrochlorideYoung AdultConceptsCore emotional symptomsDepressive severitySymptom clustersHamilton Depression Rating ScaleDepression Outcomes trialDifferent antidepressant medicationsHAM-D scaleHigh-dose duloxetinePhase 3 trialEmotional symptomsPatient-reported dataDepression Rating ScaleSequenced Treatment AlternativesGroup of symptomsCluster of symptomsDepressive symptom checklistMixed-effects regression analysisDepressive Symptomatology ScaleAntidepressant therapyAntidepressant treatmentAntidepressant medicationOutcome trialsCombining MedicationsAtypical symptomsAdditional placebo
2016
Treatment for Multiple Acute Cardiopulmonary Conditions in Older Adults Hospitalized with Pneumonia, Chronic Obstructive Pulmonary Disease, or Heart Failure
Dharmarajan K, Strait KM, Tinetti ME, Lagu T, Lindenauer PK, Lynn J, Krukas MR, Ernst FR, Li SX, Krumholz HM. Treatment for Multiple Acute Cardiopulmonary Conditions in Older Adults Hospitalized with Pneumonia, Chronic Obstructive Pulmonary Disease, or Heart Failure. Journal Of The American Geriatrics Society 2016, 64: 1574-1582. PMID: 27448329, PMCID: PMC4988873, DOI: 10.1111/jgs.14303.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAgedAged, 80 and overAnti-Bacterial AgentsCardiotonic AgentsCohort StudiesComorbidityCross-Sectional StudiesDiureticsDrug Therapy, CombinationFemaleHeart FailureHospitalizationHumansMalePneumoniaPulmonary Disease, Chronic ObstructiveRetrospective StudiesUnited StatesVasodilator AgentsConceptsChronic obstructive pulmonary diseaseAcute cardiopulmonary conditionsObstructive pulmonary diseaseHeart failureCardiopulmonary conditionsOlder adultsPulmonary diseasePremier Research DatabaseEpisodes of pneumoniaRetrospective cohort studyReal-world treatmentHF hospitalizationCohort studyHospital daysPneumonia hospitalizationsCOPD hospitalizationsClinical syndromeAcute conditionsPneumoniaDiagnostic uncertaintyResearch DatabaseHospitalizationDiagnostic categoriesU.S. hospitalsAdults
2015
Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures
Allen LA, Fonarow GC, Liang L, Schulte PJ, Masoudi FA, Rumsfeld JS, Ho PM, Eapen ZJ, Hernandez AF, Heidenreich PA, Bhatt DL, Peterson ED, Krumholz HM. Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures. Circulation 2015, 132: 1347-1353. PMID: 26316616, PMCID: PMC4941099, DOI: 10.1161/circulationaha.115.014281.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBody Mass IndexCardiovascular AgentsComorbidityContraindicationsCross-Sectional StudiesDrug HypersensitivityDrug PrescriptionsDrug SubstitutionDrug Therapy, CombinationDrug UtilizationEvidence-Based MedicineFemaleGuideline AdherenceHeart FailureHospitalsHumansMaleMedication AdherenceMiddle AgedPatient AdmissionPatient DischargePolypharmacyPractice Guidelines as TopicQuality Assurance, Health CareConceptsHF quality measuresHydralazine/isosorbide dinitrateAngiotensin receptor blockersMedication groupHeart failureAldosterone antagonistsReceptor blockersMedication regimenIsosorbide dinitrateNew medicationsΒ-blockersEnzyme inhibitorsGuideline-directed medical therapyInitiation of angiotensinPrimary discharge diagnosisQuarter of patientsPatient's medication regimenHospital quality measuresAdequate prescribingMedication initiationHospital dischargeHospital admissionMedical therapyGuideline recommendationsDischarge diagnosis
2008
Redefining Quality — Implications of Recent Clinical Trials
Krumholz HM, Lee TH. Redefining Quality — Implications of Recent Clinical Trials. New England Journal Of Medicine 2008, 358: 2537-2539. PMID: 18539915, DOI: 10.1056/nejmp0803740.Peer-Reviewed Original Research
2007
Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction: A Quantitative Review of Data From Randomized Clinical Trials
Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM. Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction: A Quantitative Review of Data From Randomized Clinical Trials. JAMA Internal Medicine 2007, 167: 1930-1936. PMID: 17923591, DOI: 10.1001/archinte.167.18.1930.Peer-Reviewed Original ResearchConceptsAngiotensin II receptor blockersSymptomatic left ventricular dysfunctionLeft ventricular dysfunctionII receptor blockersVentricular dysfunctionAdverse effectsMedication discontinuationReceptor blockersSymptomatic hypotensionRenal functionACE inhibitorsClinical trialsRelative riskEnzyme inhibitorsAngiotensin converting enzyme (ACE) inhibitorsACE inhibitor therapyHealth clinical trialsChronic heart failureRandomized clinical trialsAcute myocardial infarctionConfidence intervalsRandom-effects modelSignificant increaseEligible RCTsHeart failure
2004
Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3)
Curtis JP, Alexander JH, Huang Y, Wallentin L, Verheugt FW, Armstrong PW, Krumholz HM, Van de Werf F, Danays T, Cheeks M, Granger CB, Investigators A. Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). The American Journal Of Cardiology 2004, 94: 279-283. PMID: 15276088, DOI: 10.1016/j.amjcard.2004.04.019.Peer-Reviewed Original ResearchMeSH KeywordsAgedConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationElectrocardiographyFemaleFollow-Up StudiesHeparin, Low-Molecular-WeightHumansIncidenceIntracranial HemorrhagesMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial IschemiaPartial Thromboplastin TimeProbabilityRandomized Controlled Trials as TopicRisk AssessmentSeverity of Illness IndexSurvival RateTenecteplaseThrombolytic TherapyTissue Plasminogen ActivatorTreatment OutcomeConceptsWeight-adjusted heparinST-elevation myocardial infarctionASSENT-3Myocardial infarctionASSENT-2Major bleedingIntracranial hemorrhageSmall doseFull-dose tenecteplaseLess major bleedingNew thrombolytic regimenOutcomes of patientsAcute myocardial infarctionPartial thromboplastin timeSimilar ratesRefractory ischemiaThrombolytic regimenRecurrent infarctionBaseline characteristicsHemorrhagic complicationsUnfractionated heparinThromboplastin timePatientsInfarctionTenecteplase
2003
Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study
Curtis JP, Wang Y, Portnay EL, Masoudi FA, Havranek EP, Krumholz HM. Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. The BMJ 2003, 327: 1322. PMID: 14656840, PMCID: PMC286319, DOI: 10.1136/bmj.327.7427.1322.Peer-Reviewed Original ResearchAspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction
Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. Journal Of The American College Of Cardiology 2003, 42: 201-208. PMID: 12875751, DOI: 10.1016/s0735-1097(03)00572-2.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAnalysis of VarianceAngiotensin-Converting Enzyme InhibitorsAspirinCase-Control StudiesCohort StudiesDrug Therapy, CombinationDrug UtilizationFemaleHumansKidney Failure, ChronicLogistic ModelsMaleMyocardial InfarctionPatient SelectionPeritoneal DialysisPlatelet Aggregation InhibitorsPractice Patterns, Physicians'PrognosisRenal DialysisRisk FactorsSurvival AnalysisTreatment OutcomeUnited StatesConceptsEnd-stage renal diseaseNon-ESRD patientsAcute myocardial infarctionESRD patientsRenal diseaseMyocardial infarctionAngiotensin-converting enzyme inhibitor therapyEnd-stage renal disease patientsAngiotensin-converting enzyme inhibitorStandard medical therapyEnzyme inhibitor therapyRenal disease patientsCooperative Cardiovascular Project databaseHigh-risk populationLogistic regression modelsEarly administrationInhibitor therapyMedical therapyACE inhibitorsAMI patientsPeritoneal dialysisPoor prognosisDisease patientsESRD databasePatients
2001
Aspirin and Angiotensin-Converting Enzyme Inhibitors Among Elderly Survivors of Hospitalization for an Acute Myocardial Infarction
Krumholz HM, Chen YT, Wang Y, Radford MJ. Aspirin and Angiotensin-Converting Enzyme Inhibitors Among Elderly Survivors of Hospitalization for an Acute Myocardial Infarction. JAMA Internal Medicine 2001, 161: 538-544. PMID: 11252112, DOI: 10.1001/archinte.161.4.538.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionACE inhibitorsMyocardial infarctionInteraction of aspirinEnzyme inhibitorsAngiotensin-converting enzyme inhibitorAngiotensin converting enzyme (ACE) inhibitorsElderly patientsSecondary preventionRandomized trialsElderly survivorsLower riskAspirinPatientsMultivariate analysisHospitalizationMortalityMedicationsInfarctionInhibitorsTherapySurvivorsTrialsPrevention
1999
Sex differences in the clinical care and outcomes of congestive heart failure in the elderly
Vaccarino V, Chen Y, Wang Y, Radford M, Krumholz H. Sex differences in the clinical care and outcomes of congestive heart failure in the elderly. American Heart Journal 1999, 138: 835-842. PMID: 10539813, DOI: 10.1016/s0002-8703(99)70007-4.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsAspirinBlood PressureCardiac CatheterizationConnecticutCoronary AngiographyDiureticsDrug Therapy, CombinationFemaleFollow-Up StudiesHeart FailureHumansMaleMyocardial RevascularizationPatient ReadmissionPlatelet Aggregation InhibitorsRetrospective StudiesSeverity of Illness IndexSex CharacteristicsStroke VolumeSurvival RateTreatment OutcomeConceptsHistory of hypertensionSystolic blood pressureHeart failureMortality rateBlood pressureHeart diseaseHigher systolic blood pressureLeft ventricular systolic functionSex differencesPrevious coronary heart diseaseSimilar hospital coursesVentricular systolic functionCongestive heart failureIschemic heart diseaseCoronary heart diseaseHospital courseElderly patientsReadmission ratesRehospitalization ratesSystolic functionMale patientsVentricular functionACE inhibitorsMultivariable analysisTreatment patterns